2.26

6.43% -0.15

Heron Therapeutics Inc (HRTX)

Overview News Price History Option Chain Financials Why HRTX Down? Discussions Forecast Stock Split

Heron Therapeutics Inc stock is traded at $2.26, with a volume of 342.64K. It is down -6.43% in the last 24 hours and up +36.67% over the past month. Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Previous Close:

$2.41

Open:

$2.4

24h Volume:

342.64K

Relative Volume:

0.17

Market Cap:

$350.36M

Revenue:

$137.74M

Net Income/Loss:

$-27.97M

P/E Ratio:

-14.12

EPS:

-0.16

Net Cash Flow:

$-9.61M

1W Performance:

-4.45%

1M Performance:

+36.67%

6M Performance:

+20.59%

1Y Performance:

-25.08%

1-Day Range:

$2.25

$2.42

1-Week Range:

$2.12

$2.45

52-Week Range:

$1.04

$3.93

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name

Heron Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(858) 251-4400

Address

4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA

Employee

122

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

HRTX's Discussions on Twitter

Compare HRTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRTX Heron Therapeutics Inc	2.26	350.36M	137.74M	-27.97M	-9.61M	-0.16
VRTX Vertex Pharmaceuticals Inc	498.93	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.13	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.71	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-23-24	Initiated	CapitalOne	Overweight
Mar-13-24	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Buy
Feb-20-20	Reiterated	Needham	Buy
Jan-16-19	Reiterated	Needham	Buy
Apr-05-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Reiterated	Mizuho	Buy
Mar-01-18	Reiterated	Needham	Buy
Jan-03-18	Initiated	Leerink Partners	Outperform
Sep-27-17	Initiated	Northland Capital	Outperform
Feb-27-17	Initiated	Needham	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy
Sep-23-15	Reiterated	Leerink Partners	Outperform
Sep-02-15	Initiated	BofA/Merrill	Buy
Aug-03-15	Reiterated	Brean Capital	Buy
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform
Jun-19-15	Reiterated	Leerink Partners	Outperform
Aug-07-14	Initiated	Noble Financial	Buy

View All

Heron Therapeutics Inc Stock (HRTX) Latest News

Mar 12, 2025

Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Mar 12, 2025

Mar 11, 2025

StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - MarketBeat

Mar 11, 2025

CM Management LLC Acquires 200,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Mar 11, 2025

Why Heron Therapeutics Inc Stock Might Make Sense If Bought Today - Stocks Register

Mar 11, 2025

Mar 09, 2025

Los Angeles Capital Management LLC Sells 153,181 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Mar 09, 2025

Principal Financial Group Inc. Raises Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Mar 09, 2025

Heron Therapeutics (HRTX) to Release Quarterly Earnings on Tuesday - Defense World

Mar 09, 2025

Mar 08, 2025

Heron Therapeutics: Four Horse Race Of Approved Therapies (NASDAQ:HRTX) - Seeking Alpha

Mar 08, 2025

Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World

Mar 08, 2025

Mar 07, 2025

Heron Therapeutics (NASDAQ:HRTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Mar 04, 2025

Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Mar 04, 2025

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO. - MarketBeat

Mar 04, 2025

Mar 03, 2025

Heron Therapeutics (NASDAQ:HRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm - accessnewswire.com

Mar 03, 2025

Brokers Offer Predictions for HRTX Q1 Earnings - Defense World

Mar 03, 2025

Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Mar 03, 2025

Mar 02, 2025

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

Mar 02, 2025

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 02, 2025

Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by StockNews.com - Defense World

Mar 02, 2025

Mar 01, 2025

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St

Mar 01, 2025

Feb 28, 2025

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

High Growth Tech Stocks to Watch in US Market February 2025 - Yahoo Finance

Feb 28, 2025

Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years - Simply Wall St

Feb 28, 2025